Here’s Why Horizon Therapeutics Public Limited Company (HZNP) Surged in Q4

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the mid-cap stocks posted solid gains. On the other hand, its full-year returns were disappointing. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower Advisors highlighted stocks like Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in the Q4 2022 investor letter. Headquartered in Dublin, Ireland, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a biotechnology company. On January 16, 2023, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) stock closed at $113.24 per share. One-month return of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) was 0.24%, and its shares gained 24.30% of their value over the last 52 weeks. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has a market capitalization of $25.701 billion.

Carillon Tower Advisors made the following comment about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in its Q4 2022 investor letter:

“Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) focuses primarily on the research, development, and marketing of late-stage biopharmaceutical products. Shares jumped after it was announced the company was in talks with a number of noteworthy players in the biopharmaceutical industry about a potential sale.”

Tonhom1009/Shutterstock.com

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 57 hedge fund portfolios held Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) at the end of the third quarter, which was 67 in the previous quarter.

We discussed Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in another article and shared Renaissance Investment’s views on the company. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.